GET DAILY SIGNALSBiodesix (BDSX) Shares Fall -57% in 30 Days After Q3 Miss and Guidance Reduction
Key Takeaways
- Biodesix (BDSX) shares have dropped roughly 57% over the last 30 days, sliding from about $25.70 to near $11 per share.
- The bulk of the decline came in a single session after third-quarter 2026 revenue missed expectations and management cut full-year guidance.
- Company leadership cited sales-force turnover, primary-care seasonality, and delayed development-services projects as the primary drags on growth.
- Several analysts trimmed price targets after the report, while multiple law firms announced investigations into the company's disclosures.
- Despite the selloff, gross margin held near 81% and diagnostic test volumes still grew double digits year over year.
Company Background and Market Position
Biodesix, Inc. is a diagnostic solutions company headquartered in Louisville, Colorado, focused on lung disease. The company develops and commercializes blood-based tests used across the lung cancer care continuum. Its Nodify Lung tests — Nodify CDT and Nodify XL2 — help physicians assess the risk of cancer in suspicious lung nodules, while its IQLung testing strategy, comprising GeneStrat ddPCR, GeneStrat NGS, and VeriStrat, guides treatment decisions following a lung cancer diagnosis. The company also operates a Development Services segment that provides testing and consulting to biopharmaceutical and life sciences companies.
Investors follow BDSX for its position in the large, underserved market for lung nodule risk assessment, its industry-leading gross margins (consistently above 80%), and its pipeline of molecular residual disease (MRD) and digital diagnostics programs developed alongside partners such as Bio-Rad Laboratories and Thermo Fisher Scientific. The company remains unprofitable on a net basis, which makes revenue execution and sales-force productivity closely watched metrics. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance Over the Last 30 Days and Quarter
Over the last 30 days, BDSX has fallen approximately 57%, declining from a closing price near $25.70 to roughly $11. The move was not gradual. Most of the loss occurred on November 6, 2026, when the stock plunged from $19.84 to close at $8.53 — a single-day decline of about 57% — before recovering modestly into the $10–$11 range in subsequent sessions.
The quarterly trend tells a similar story of reversal. After trading near its 52-week high of $31.97 in late September 2026, the stock has lost roughly 57% over the trailing three months. Even so, BDSX remained up substantially on a year-to-date basis, reflecting a strong first half of the year before the sharp September-to-November drawdown. The rapid decline pushed the stock well below its 50-day moving average and into deeply oversold territory on short-term technical measures.
What Drove the Recent Price Action
The catalyst for the collapse was the company's third-quarter 2026 earnings report, released November 5, 2026. Biodesix reported total revenue of $24.0 million, up 10% year over year but below analyst expectations, and lowered its full-year 2026 revenue guidance to a range of $101 million to $103 million, down from a prior range of $108 million to $114 million.
Management attributed the shortfall to "execution and timing challenges," citing an average of roughly 101 sales representatives during the quarter — below plan — because of elevated turnover and a hiring pace that lagged attrition. A larger share of the commercial effort was therefore directed at maintaining existing accounts rather than acquiring new ordering physicians. The company also pointed to greater-than-anticipated seasonality in primary care and customer delays in starting several development-services projects. Gross margin remained strong at about 81%, and diagnostic test volumes rose roughly 24% year over year, but the guidance cut outweighed those positives in investors' eyes.
The selloff was amplified by sell-side revisions and legal scrutiny. Analysts at Lake Street, TD Cowen, and H.C. Wainwright lowered their price targets following the results, and firms including Kirby McInerney LLP and Johnson Fistel announced investigations into potential securities-law claims related to the company's disclosures. A subsequent shelf registration filing added to concerns about potential future dilution.
Broader Context Behind the Quarterly Decline
The quarterly decline reflects a broader re-rating of a high-growth, money-losing small-cap after its momentum reversed. Through much of 2026, BDSX rallied on accelerating revenue growth, expanding sales coverage into primary care, and positive clinical catalysts, including a new framework from the CHEST medical society that incorporated biomarkers such as Nodify into lung nodule management programs. The stock reached its 52-week high near $32 in late September.
That optimism collided with the reality of commercial execution in the third quarter. The sales-force gap and primary-care seasonality exposed how sensitive the growth story is to hiring and productivity, while the guidance cut reset expectations for near-term revenue. The result was a rapid repricing from premium growth multiples toward a level more consistent with a company still generating net losses and relying on continued capital raises. Longer-term programs — including the MRD collaborations with Bio-Rad Laboratories and Thermo Fisher Scientific and a radiomics-based digital diagnostics platform being developed with Vanderbilt University — remain intact but did not offset the near-term execution concerns.
What Investors Should Watch Next
Investors will be watching several factors that could shape BDSX's trajectory. First is sales-force stabilization: whether the company can reach its target of roughly 115 field representatives and restore new-physician acquisition will be central to reaccelerating diagnostic test revenue. Second is the durability of the guidance reset — any further adjustments to the $101 million to $103 million range would likely pressure the stock further, while signs of stronger order trends could support a rebound.
Additional items to monitor include payer reimbursement developments and average selling prices, the timing of development-services project starts, and progress on the MRD programs and the digital diagnostics platform, including initial data expected at the RSNA meeting in December 2026. The pending legal investigations and any resulting litigation, as well as the company's capital position and potential for further share issuance, also represent meaningful risks. As always, these are factors to track rather than guarantees of any particular outcome. From what I see, I'm watching this closely for any signs of stabilization in the sales metrics.
Integrating AI Tools Into My Research Process
I often turn to Tickeron’s AI Trading Bots for additional perspective on market movements like this one. The platform’s automated strategies help surface data-driven signals across thousands of tickers, allowing me to compare BDSX performance against broader trends without replacing my fundamental analysis. It serves as one more layer in evaluating opportunities alongside traditional research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for BDSX turns negative, indicating new downward trend
BDSX saw its Momentum Indicator move below the 0 level on October 30, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned negative. In 79 of the 86 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
BDSX moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BDSX crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDSX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for BDSX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +12.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where BDSX advanced for three days, in 202 of 237 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
BDSX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.843) is normal, around the industry mean (67.298). P/E Ratio (-2.752) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.463) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating fairly steady price growth. BDSX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BDSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalSpecialties
Advertisement